Evidence map›Paper›PMID 36713556›Full record

ArticleFrontiers in oncology2022

Presentation and management outcomes of Retinoblastoma among Syrian refugees in Jordan.

Yacoub A Yousef, Qusai F Abu Salim, Mona Mohammad, Imad Jaradat, Mustafa Mehyar, Reem AlJabari, Omar Al-Habahbeh, Khalid Saboubeh, Hadeel Halalsheh, Jakub Khzouz and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Yacoub A YousefDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Qusai F Abu SalimDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Mona MohammadDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Imad JaradatDepartment Radiation Oncology, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Mustafa MehyarDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Reem AlJabariDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Omar Al-HabahbehDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Khalid SaboubehDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Hadeel HalalshehDepartment Pediatrics Oncology, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Jakub KhzouzDepartment Pathology and Laboratory Medicine, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Munir ShawagfehDepartment Anesthesia, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Iyad SultanDepartment Pediatrics Oncology, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Mahmoud AlMasriDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Ibrahim Al-NawaisehDepartment of Surgery, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Maysa Al-HussainiDepartment Pathology and Laboratory Medicine, King Hussein Cancer Centre (KHCC), Amman, Jordan.
Asem MansourDepartment Diagnostic Radiology, King Hussein Cancer Centre (KHCC), Amman, Jordan.
King Hussein Cancer Center · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The humanitarian crisis in Syria has had a profound impact on the entire region. In this study, we report the patterns of presentation and management outcomes of Syrian patients with Retinoblastoma (Rb) treated at a single tertiary cancer center in Jordan. Methods and Materials: This is a retrospective comparative study of Syrian refugees and Jordanian citizens who had Rb between 2011 and 2020. Collected data included patient demographics, presentation, tumor stage, treatment modalities, eye salvage rate, metastasis, and mortality. Results: Thirty Syrian refugees (16 (53%) had bilateral disease) and 124 Jordanian citizens (51(41%) had bilateral disease) were diagnosed with Rb during this period. The median age at diagnosis for refugees was 10 and 32 months for patients with bilateral and unilateral Rb consecutively, compared to 6 and 28 months for citizens. The median lag time between signs of disease and initiation of treatment was 3 months for refugees, compared to 1 month for citizens.Refugees were more likely to present with a more advanced stage (p=0.046). Out of 46 affected eyes in refugees; 32 (70%) eyes were group D or E, while out of 175 affected eyes among citizens; 98 (56%) eyes were group D or E. Therefore, refugees with Rb were more likely to mandate primary enucleation (48%) compared to citizens (25%) (p=0.003). However, out of 24 eyes among refugees who received conservative therapy, 15 (62%) eyes were successfully salvaged, while out of 131 affected eyes among citizens who received conservative therapy, 105 (80%) eyes were successfully salvaged (p=0.06). Two (7%) of the refugees and four (3.2%) of the citizens with Rb died from metastasis. Conclusion: Syrian refugees with Rb presented with more advanced disease due to delay in diagnosis and referral that increased the treatment burden by decreasing the chance for eye globe salvage. However, patients who received the timely intervention had a similar outcome to citizens with Rb; probably a reflection of the management of all patients at a single specialized center. We advocate for the timely referral of refugees with this rare life-threatening tumor to a specialized cancer center for the best possible outcome.

Indexed as

enucleationeye salvagerefugeesRetinoblastomasurvival

Identifiers

PMID36713556
PMCPMC9880551
OpenAlexW4315797331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.